Compare SQM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQM | ILMN |
|---|---|---|
| Founded | 1968 | 1998 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 20.5B |
| IPO Year | 1993 | 2000 |
| Metric | SQM | ILMN |
|---|---|---|
| Price | $73.94 | $134.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 17 |
| Target Price | $66.85 | ★ $125.71 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 03-03-2026 | 02-05-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 1.84 | ★ 4.46 |
| Revenue | ★ $4,326,111,000.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.11 | $2.79 |
| P/E Ratio | $43.19 | ★ $30.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.36 | $68.70 |
| 52 Week High | $86.13 | $155.53 |
| Indicator | SQM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 40.12 |
| Support Level | $75.00 | $147.57 |
| Resistance Level | $79.31 | $153.48 |
| Average True Range (ATR) | 3.18 | 5.44 |
| MACD | -1.42 | -2.30 |
| Stochastic Oscillator | 7.16 | 8.54 |
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.